focus -WSS

focus

author：focus 2025-09-30 23:20:05 - browse：28

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Duchenne patients, backed by ‘dark money’ group, to debate drug prices

WSS

Studies point to risks of excluding people with obesity from drug trials

Impact of Dobbs ruling felt at reproductive medicine meeting

Make 'food is medicine' a key part of White House nutrition meeting

Listen: Biogen's messy board & Laronde's data problem

Bacterial infection may be ‘key event’ in endometriosis, study says

Listen: Biogen's messy board & Laronde's data problem

entertainment

focus

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

When is a doctor not a doctor? Try when patients address women doctors

BioMarin wins approval for gene therapy to treat hemophilia A

Grail is spending more than ever lobbying Congress

Apple is now the first public company to be valued at $3 trillion

Option Care buys Amedisys in $3.6 billion home care deal

At least 13 dead in Texas as scorching temps continue

STAT Summit: Michael J. Fox on progress in Parkinson's research

Medicare details structure of new drug price negotiation program

Studies point to risks of excluding people with obesity from drug trials

focus

Will Ozempic

Listen: Biogen's messy board & Laronde's data problem

STAT Summit: Biotech founders on deal

Lawmakers consider Medicare pay reforms for doctors

Doctor appointment wait times are getting worse

A new study asks: Are we harming blood donors by taking blood?

Wikipedia

entertainment

explore

Wikipedia